Psoriasis drug achieves phase III endpoint

Article

Efalizumab (Raptiva), an investigational therapy for moderate-to-severe psoriasis, achieved its primary efficacy endpoint in a randomized phase III study.

Related Videos
Related Content

Julie Harper, MD to Present a Rosacea Research Roundup and Pearls

September 27th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Make the Most of Your Visit to Asheville for Maui Derm NP + PA Fall 2023

September 27th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

POLL: Are You Attending Maui Derm NP+PA Fall 2023?

September 26th 2023

Journal Digest: September 26

September 26th 2023

Julie Harper, MD to Present a Rosacea Research Roundup and Pearls

September 27th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Make the Most of Your Visit to Asheville for Maui Derm NP + PA Fall 2023

September 27th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

POLL: Are You Attending Maui Derm NP+PA Fall 2023?

September 26th 2023

Journal Digest: September 26

September 26th 2023

Julie Harper, MD to Present a Rosacea Research Roundup and Pearls

September 27th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Make the Most of Your Visit to Asheville for Maui Derm NP + PA Fall 2023

September 27th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

POLL: Are You Attending Maui Derm NP+PA Fall 2023?

September 26th 2023

Journal Digest: September 26

September 26th 2023
© 2023 MJH Life Sciences

All rights reserved.